Ozone therapy immunomodulatory effect in the selective immunoglobulin A deficiency.


The aim of this work is to study the ozone therapy effect in the selective immunoglobulin A deficiency. Taking into account that ozone is able to stimulate several biological systems, to modulate cytokines levels and to enhance immunoglobulin production, a phase II, controlled and randomized, clinical trial was performed. Forty patients were divided at random into 2 groups of 20 patients each: Ozone – received 42 sessions by rectal insufflations during three months, using scaling doses. Control – received subcutaneous Hebertrans during three months. Patients were evaluated at the beginning and one and six months later. The IgA improved, with significant difference (p=0.04) between both groups. The blood levels of IgG were increased significantly (p=0.03) in the group treated with ozone compared to the control group. Leukocyte activity improved significantly (p=0.04) one month later, achieving 97 % of normal values. The clinical evolution was satisfactory in 87 and 80 % of the children that received ozone and Hebertrans, respectively without side effects reported.


ozone thrapy; inmunology; selective IgA deficiency; immunological parameters; cytokines; subcutaneous Hebertrans

Full Text:



  1. Bradley AL, Trivikram D, James WV. Laboratory Diagnosis of Primary Immunodeficiencies. Clinic Rev Allerg Immunol. 2014;46:154-168.

  2. Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Frontiers in immunology. 2014;5(162):1-32.

  3. Abbas AK. Regional Immunity: Specialized immune response in epithelial and immune privileged tissues. In: Abbas AK, Lichtman A. Cellular and Molecular Immunology. 7 ed. NY: WB Saunders Co; 2011.

  4. Abbas AK. Congenital and acquired immunodeficiencies: Specialized immune response in epithelial and immune privileged tissues. In: Abbas AK, Lichtman A. Cellular and Molecular Immunology. 7 ed. NY: WB Saunders Co; 2011.

  5. Yel L. Selective IgA deficiency. J Clin Immunol. 2010;30(1):10-6.

  6. Bezrodnik L, Giovanni D, Ginaca A. Evaluación clínica e inmunológica de 90 pacientes con deficiencia selectiva de inmunoglobulina A. Arch Argent Pediatr. 2008;10(5):375-381.

  7. Singh K, Chang C, Gershwin ME. IgA deficiency and autoimmunity. Autoimmunity Reviews. 2014;13(2):163-177.

  8. Fitzsimons MG, Walton K, Makar R, Dzik W, Kuter D, Vlahakes GJ. Redo aortic valve replacement in a patient with immunoglobulin A deficiency and hemophilia A. Ann Thorax Surg. 2013;96(1):311-313.

  9. Domínguez O, Giner MT, Alsina L, Martín MA, Lozano J, Plaza AM. Fenotipos clínicos asociados a la deficiencia selectiva de IgA: revision de 330 casos y propuesta de un protocolo de seguimiento. An Pediatr. 2012;76(5):261-267.

  10. Unknown-author. Transfer factor. Available from: [Accessed 1th Mar 2009]

  11. Inclan G, et al. Immunological and clinical response in patients with IgA deficiency after the treatment with transfer factor. Haematol immunol and Haemotherapy. 1994;10:80-81.

  12. Bocci V. Biological and clinical effects of ozone. Has ozone therapy a future in medicine?. British Journal of Biomedical Science. 1999;56(4):270-279.

  13. Menendez S, Gonzalez R, Ladea OE, Leon OS, Hernandez F, Díaz M. Ozonoterapia: Aspectos basicos y aplicaciones clínicas. La Habana, Cuba: Editorial CENIC; 2008.

  14. Larini A, Bocci V. Effects of ozone on isolated peripheral blood mononuclear cells. Toxicology in Vitro. 2005;19:55-61.

  15. Bocci V. Scientific and medical aspects of ozone Therapy. State of the art. Arch Med Res. 2006;37:425-435.

  16. Travagli V, Zanardei I, Silvietti A, Bocci V. A physicochemical investigation on the effect of ozone on blood. Int J Biol Macromol. 2007;41:504-511.

  17. Bocci V, Borrelli E, Corradeshi F, Valacchi G. Systemic effects after colorectal insufflations of oxygen-ozone in rabbits. Int J Med Biol Environ. 2000;28:109-113.

  18. Ajamieh HH, Menendez S, Merino N, Martínez G, Re L, Leon OS. Ischemic and ozone oxidative preconditioning in the protection against hepatic ischemic-reperfusion injury. Ozone Sci Eng. 2003;25(3):241-50.

  19. Calunga JL, Trujillo Y, Menendez S, Zamora Z, Alonso Y, Merino N, et al. Ozone oxidative postconditioning in acute renal failure. J Pharm Pharmacol. 2009;61:1-7.

  20. Martinez G, Al-Dalain SM, Menendez S, Re L, Giuliani A, Candelario-Jalil E, et al. Therapeutic efficacy of ozone medical treatments in patients with diabetic foot. Eur J Pharmacol. 2005;523:151-161.

  21. Hernandez F, Calunga JL, Turrent J, Menendez S, Montenegro A. Ozone therapy effects on blood biomarkers and lung fuction of asthma patients. Arch Med Res. 2005;36(5):549-554.

  22. Ajamieh HH, Menendez S, Martinez-Sanchez G, Candelario-Jalil E, Re L, Giuliani A, et al. Effects of ozone oxidative preconditioning on nitric oxide generation and cellular redox balance in a rat model of hepatic ischaemia-reperfusion. Liver Int. 2004;24:55-62.

  23. Viebahn R. The use of ozone in Medicine. 3rd English ed. Iffezheim, Germany: ODREI-Publishers; 1999.

  24. Alonso I, et al. Formulario Nacional de Medicamentos. Segunda edicion. La Habana: Ed. Ciencias Medicas; 2011.

  25. Hoffman R, Benz EJ, Shattil SS, et al. Hematology: Basic Principles and Practice. 4th ed. Orlando, Fl: Churchill Livingstone; 2005.

  26. Ronald JH, Giclas PC. Diagnostic Immunology Laboratory Manual. New York, USA: Raven Press; 1991.

  27. Suardíaz J, Cruz C, Colina A. Laboratorio Clinico. 1 ed. La Habana: Editorial Ciencias Medicas; 2004.

  28. Weber-Mezell D, Kotanko P, Hauer AC, et al. Gender, age and seasonal effect on IgA deficiency: A study of 7293 Caucasians. Eur J Clin Invest. 2004;34(3):224-229.

  29. Mendez IJ, Bellanti JA, Ovilla MR. Inmunodeficiencias primarias y alergia. Alerg Asma Inmunol Pediatr. 2008;17(1):14-34.

  30. Urm SH, Yun HD, Fenta YA, Yoo KH, Abraham RS, Hagan J. Asthma and risk of selective IgA deficiency or common variable immunodeficiency: a population-based case-control study. Mayo Clin Proc. 2013;88(8):813-21.

  31. Notarangelo L, Casanova JL, Fisher A, Puck J, Rosen F, Seger R, Geha G. Primary immunodeficiency diseases: Na update. J Allergy Clin Immun. 2004;114:677-687.

  32. Barrios M. Clinical evolution of the patient default of IgA treated with Transference factor. Hemat Imm Transf Med. 2004;20(3):180-184.

  33. Bocci V, Luzzi E, Corradeshi F, Paulesu L, Di-Stefano A. Studies on the biological effects of ozone. An attempt to define conditions for optimal induction of cytokines. Lymphokine and Cytokine Res. 1993;12:121-126.

  34. Bocci V. Ozonization of blood for the therapy of viral diseases and immunodeficiencies. A hypothesis. Medical hypotesis. 1992;39:30-34.

  35. Bocci V, Borrelli E, Zanardi I, Travagli V. Oxygen-ozone therapy is at a cross-road. Revista Española de Ozonoterapia. 2011;1(1):74-86.

  36. Paulesu L, Luzzi E, Bocci V. Studies on the biological effects of ozone: 2. Induction of tumor necrosis factor (TNF ά) on human leucocytes. Lymphokines Cytokines Res. 1991;10:409-412.

  37. Curse JM, Lewis RE. Atlas of Immunology. Second Edition. Florida: CRC Press; 2004.

  38. Rhee SG, Bae YS, Lee SR, Kwon J. Hydrogen peroxide. A key messenger that modulates protein phosphorylation though cysteine oxidation. Sci STKE. 2000;2000(53):1. PubMed PMID: 11752613. doi: 10.1126/stke.2000.53.pe1.

  39. Stites DP, Terr AI, Parslow TG. Inmunologia basica y clinica. Novena Edicion. Mexico: El Manual Moderno, S.A de C.V; 1998.

  40. Lekstrom-Himes JA, Gallin JI. Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med. 2000;343:1703-1713.

  41. Aderem A. Underbil DM. Mechanism of phagocytes in Macrophages. Ann Rev Immunol. 2009;170:553-623.

  42. Guanche D, Zamora Z, Hernandez F, et al. Effect of ozone/oxygen mixture on systemic oxidative stress and organic damage. Toxicol Mech Methods. 2010;20(1):25-30.

  43. Aubourg P. L'ozone medical: Production, posologie, modes d'applications cliniques. Bull Med Soc Med Paris. 1938;52:745-749.

  44. Bocci V. Is it true that ozone is always toxic? The end of a dogma. Toxicol Appl Pharm. 2006;216:493-504.


  • There are currently no refbacks.

WFOTJournal of Ozone Therapy (JO3T)
The Official Peer Reviewed Journal of the World Federation of Ozone Therapy (WFOT)
ISSN 2444-9865